Compositions for treating diabetic retinopathy and methods of using same

• US 6,852,688 B2
• Filed: 03/12/2001
• Issued: 02/08/2005
• Est. Priority Date: 03/10/2000
• Status: Expired due to Fees

• Current Assignee: University of Florida (State University System of Florida)
• Original Assignee: University of Florida (State University System of Florida)
• Inventors: Grant, Maria
• Primary Examiner(s): RUSSEL, JEFFREY E
• Application Number:
  US09/804,484
• Publication Number:
  US 20020045569A1
• Time in Patent Office: 1,429 Days
• Field of Search: 514/8, 514/11, 514/14, 514/16, 514/21, 514/567, 530/311, 530/397, 564/447, 562/447
• US Class Current: 514/6.9
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/31 Somatostatins

Abstract

The subject invention provides novel methods and materials for treating diabetic retinopathy. One embodiment of the subject invention involves the co-administration of a somatostatin, or analogue thereof, and a thryoid-related substance such as thyroxine. Somatostatin or thyroid-related substance can be administered in combination, or separately through the same or different modes of administration.

Claims

1. A method of treating or preventing the onset of diabetic retinopathy in a patient comprising administering somatostatin to said patient and co-administering a thyroid-related substance.

2. The method of claim 1, wherein said somatostatin is octreotide, lanreotide, vapreotide, MK 678, L-363-377, L-797,591, L-779,976, L-796-778, L-803,087, L-817,818, or combinations thereof.

3. The method of claim 1, wherein said thyroid related substance is thyroid hormone, thyroxine, thyrotropin, thyroid stimulating hormone, or analogues or, pharmaceutically acceptable salts or derivatives thereof that have similar biological functionality or effect in the body.

4. A composition useful for treating or preventing the onset of DR comprising a mixture of somatostatin and a thyroid-related substance.

5. A kit comprising at least one container having somatostatin and a thyroid-related substance disposed therein.

6. The kit of claim 5 further comprising a syringe for administration of the somatostatin and thyroid-related substance.

7. The kit of claim 6 wherein at least one container is one or more syringes having somatostatin and thyroid-related substance disposed in either one syringe as a mixture or in separate syringes.

8. The kit of claim 5 wherein the somatostatin and thryroid-related substance is in a form suitable for oral administration.

9. A method of treating or preventing the onset of DR comprising administering somatostatin and co-administering a thyroid-related substance, wherein the dosage of said somastostatin and said thyroid-related substance is of an amount such that any synergistic effect of said administering or co-administering is optimized.

10. An article of manufacture comprising somatostatin and thyroid-related substance.

11. The article of manufacture of claim 10 in the form of a solid or liquid.

12. A method of treating or preventing the onset of diabetic retinopathy comprising assaying a group of somatostatin analogues for their ability to bind to a sstr2 somatostatin receptor;

selecting one or more analogues having high affinity to said sstr2 somatostatin receptor; and

administering said one or more selected analogues to a patient in need thereof; and

co-administering a thyroid-related substance.

13. The method of claim 12 wherein said high affinity comprises a K_i, value in nanomoles of about 2 or less.

14. A method of treating or preventing DR in a patient comprising identifying whether said patient is susceptible to developing DR;

administering somatostatin to said individual; and

co-administering a thyroid related substance.

15. The method of claim 14, wherein said thyroid related substance is thyroxine delivered in an amount of 100-200 μ

g a day.